Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
With a market cap of 74.12B, Regeneron(REGN) trades at $701.42. The stock has a price-to-earnings ratio of 17.23 and currently yields dividends of 50.6%.
As of 2026-05-01, Regeneron(REGN) stock has fluctuated between $700.26 and $714.48. The current price stands at $701.42, placing the stock +0.2% above today's low and -1.8% off the high.
Regeneron(REGN) shares are trading with a volume of 703K, against a daily average of 845.86K.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.
REGN News
Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $995 from $975 and keeps a Buy rating on the shares after a “strong perfor...
In a report released on April 29, Salveen Richter from Goldman Sachs assigned a Buy rating on Regeneron, with a price target of $968.00. Unlock hedge fund-leve...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron yesterday and set a price target of $900.00. Unlock hedge fund-level data and powerful...
Analyst ratings
77%
of 31 ratingsMore REGN News
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consen...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Technology Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug Licensing Regeneron stock dipped early Wednesday after the biotech giant repo...
Regeneron (REGN) came out with quarterly earnings of $9.47 per share, beating the Zacks Consensus Estimate of $8.52 per share. This compares to earnings of $8.2...
In April 2026, Regeneron Pharmaceuticals and partner Sanofi reported a series of milestones including FDA accelerated approval for Otarmeni, expanded U.S. pedia...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.